Last reviewed · How we verify

Soligenix, Inc. — Portfolio Competitive Intelligence Brief

Soligenix, Inc. (SNGX) pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

SNGX (NASDAQ) 0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
SGX301 (synthetic hypericin) SGX301 (synthetic hypericin) phase 3 Photosensitizer Hypericin (photosensitizing agent); generates ROS upon light activation Oncology; Dermatology
SGX942 SGX942 phase 3 Growth factor PDGF-BB Wound healing

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Adocia · 1 shared drug class
  2. Australasian Gastro-Intestinal Trials Group · 1 shared drug class
  3. Centre Oscar Lambret · 1 shared drug class
  4. Chinese PLA General Hospital · 1 shared drug class
  5. Genzyme, a Sanofi Company · 1 shared drug class
  6. Hyuk moon Kim · 1 shared drug class
  7. SVS Institute of Dental Sciences · 1 shared drug class
  8. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Soligenix, Inc.:

Cite this brief

Drug Landscape (2026). Soligenix, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/soligenix. Accessed 2026-05-13.

Related